Cybin Inc. to Present at Cantor Global Healthcare Conference on Neuropsychiatry Developments
TL;DR
Cybin's CMO will present at the Cantor Global Healthcare Conference, offering investors early insights into the company's breakthrough mental health treatments and potential market advantages.
Cybin's CMO will discuss Phase 3 trials for CYB003 and Phase 2 studies for CYB004 during a fireside chat webcast on September 5, 2025 at 10:20 AM ET.
Cybin's innovative mental health treatments could provide effective and durable relief for millions suffering from depression and anxiety disorders worldwide.
Cybin is developing novel deuterated psychedelic compounds that have received FDA Breakthrough Therapy Designation for treating major depressive disorder and anxiety.
Found this article helpful?
Share it with your network and spread the knowledge!
Cybin Inc., a clinical-stage neuropsychiatry company, announced that Chief Medical Officer Amir Inamdar will participate in a fireside chat at the Cantor Global Healthcare Conference scheduled for September 3-5, 2025. The session will be webcast live on Friday, September 5, at 10:20 a.m. ET, with an archived replay available on Cybin's investor relations website at https://ibn.fm/N8ObB.
The company's participation in this prominent healthcare conference underscores the growing importance of innovative mental health treatments and the pharmaceutical industry's focus on addressing the substantial unmet needs in neuropsychiatry. Cybin is developing next-generation treatment options that could potentially revolutionize mental healthcare delivery and outcomes for patients worldwide.
Cybin's clinical pipeline includes CYB003, a proprietary deuterated psilocin analog currently in Phase 3 studies for adjunctive treatment of major depressive disorder. This investigational therapy has received Breakthrough Therapy Designation from the U.S. Food and Drug Administration, indicating its potential to demonstrate substantial improvement over existing treatments. The company is also advancing CYB004, a proprietary deuterated N, N-dimethyltryptamine molecule in Phase 2 study for generalized anxiety disorder.
The company maintains a research pipeline of investigational compounds focused on 5-HT receptors, targeting various mental health conditions. Founded in 2019, Cybin operates in Canada, the United States, the United Kingdom, and Ireland, reflecting the global nature of mental health challenges and the international collaboration required to develop effective treatments.
This conference appearance comes at a critical time when mental health disorders affect millions worldwide, with traditional treatments often providing inadequate relief or causing significant side effects. The development of novel neuropsychiatry treatments represents a significant advancement in addressing these challenges, potentially offering more effective and durable results for patients suffering from conditions that have historically been difficult to treat effectively.
The Cantor Global Healthcare Conference provides a platform for Cybin to share updates on its clinical progress and research developments with investors, healthcare professionals, and industry stakeholders. The webcast availability ensures broader access to this information, allowing interested parties worldwide to stay informed about advancements in mental health treatment research. Additional information about Cybin's developments is available through the company's newsroom at https://ibn.fm/CYBN.
Curated from InvestorBrandNetwork (IBN)
